Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Drummond, A; Pichler, J; Argenziano, G; Zalaudek, I; Longo, C; Lallas, A; Piana, S; Moscarella, E.
Lichen planopilaris after imiquimod 5% cream for multiple BCC in basal cell naevus syndrome.
Australas J Dermatol. 2015; 56(4):e105-e107 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Zalaudek Iris
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Basal cell naevus syndrome is an inherited autosomal dominant genetic disorder characterised by multiple basal cell carcinomas (BCC), skeletal, neurological and opthalmological abnormalities. The treatment of choice of the often multiple and large BCC consists of a combined approach including surgery, liquid nitrogen and other topical treatment modalities. Imiquimod 5% cream is an immune-response-modifying drug with antiviral and anti-tumour activity. Recent reports have associated the immune-stimulant properties of imiquimod with the exacerbation of several autoimmune skin diseases, such as eczema, psoriasis, vitiligo and lichenoid dermatitis. Here we report a patient with basal cell naevus syndrome who developed a lichen planopilaris on the same site of the scalp, which had been previously treated with two cycles of imiquimod for multiple BCC. © 2014 The Australasian College of Dermatologists.
Find related publications in this database (using NLM MeSH Indexing)
Alopecia - chemically induced
Aminoquinolines - adverse effects
Antineoplastic Agents - adverse effects
Basal Cell Nevus Syndrome - drug therapy
Drug Eruptions - etiology
Female -
Head and Neck Neoplasms - drug therapy
Humans -
Imiquimod -
Lichen Planus - chemically induced
Middle Aged -
Scalp -
Skin Cream - adverse effects
Skin Neoplasms - drug therapy

Find related publications in this database (Keywords)
Gorlin-Goltz
imiquimod 5%
lichen planopilaris
© Meduni Graz Impressum